This study is looking at how safe a drug called migalastat is for people with Fabry disease who also have kidney problems. Fabry disease is a genetic condition that affects the body's ability to break down a certain fat, leading to health problems. The study includes people whose kidneys are not working well (eGFR < 30 mL/min/1.73 m²), a measure of kidney function. Some participants may be on dialysis, which is a treatment that helps clean the blood when kidneys can’t.
There are two groups in this study:
- Group 1: Patients with severe kidney problems not on dialysis.
- Group 2: Patients with end-stage kidney disease who are on specific types of dialysis.
To join, participants must be 18 or older, have a type of Fabry disease that responds to migalastat, and have a low eGFR. They should not have had a kidney transplant or be on other specific drugs.
- Duration: Screening followed by study visits over several weeks.
- Location: Study clinic or affiliated dialysis center.
- Eligibility: Must meet specific health criteria and commit to study requirements.
How understandable was the trial content above?
Hard to understand
Easy to understand